版本:
中国

BRIEF-Prothena outlines phase 2 development strategy for PRX003

Sept 29 Prothena Corporation Plc :

* Plans to advance a phase 2 clinical study of PRX003 for treatment of Psoriatic Arthritis

* Interim analysis of ongoing phase 1B multiple ascending dose proof-of-biology study in patients with Psoriasis expected by mid-2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐